PNC-27 (30mg)
PNC-27 is an antineoplastic peptide that targets the HDM-2 receptor on cancer cells, inducing pore formation in their membrane and causing cell necrosis. It does not harm healthy cells. 30 mg vial for subcutaneous administration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
PNC-27 contains an HDM-2 binding domain (a p53 inhibitor) and an amphipathic sequence. It binds to HDM-2 on the surface of cancer cells, forming pores in the membrane that lead to necrosis. Healthy cells do not overexpress HDM-2 and are therefore unaffected.
Quick Start
- Reconstitution: Add 1.5 mL of bacteriostatic water → 20 mg/mL.
- Typical dose: 1–3 mg daily.
- Easy measurement: At 20 mg/mL, 5 units = 1 mg.
- Storage: −20 °C / 2–8 °C after reconstitution.
Dosing Table — PNC-27 30mg
Route: Subcutaneous | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 1 mg | 5 Units (0.05 mL) |
| Weeks 3–4 | 2 mg | 10 Units (0.10 mL) |
| Weeks 5–8 | 3 mg | 15 Units (0.15 mL) |
Studies report administration once daily subcutaneously. 4–8 week cycle, with gradual titration.
Related compounds
Reconstitution Steps
- Withdraw 1.5 mL of bacteriostatic water.
- Inject slowly down the side wall.
- Swirl gently.
- Refrigerate at 2–8 °C.
Protocol Overview
- Objective: Research protocol for antineoplastic action.
- Schedule: Daily injections for 4–8 weeks.
- Mechanism: Targeted destruction of cells overexpressing HDM-2.
Dosing Protocol
- Start: 1 mg/day.
- Increase: 2 mg after 2 weeks.
- Target: 3 mg/day for weeks 5–8.
- Break between cycles: After the cycle (4–8 weeks), a washout period of 4–6 weeks is recommended. Research use only — medical evaluation is required before restarting.
Washout & Cycle Restart
When can I restart?
After the cycle (4–8 weeks), a washout period of 4–6 weeks is recommended. Research use only — medical evaluation is required before restarting.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C.
- Reconstituted: 2–8 °C · use within 3 weeks.
Important Notes
- For research use only.
- Use sterile technique.
Potential Benefits & Side Effects
Potential Benefits:
- Selective action on cancer cells.
- Does not harm healthy cells.
- Induces pore formation in cancer cell membranes.
Potential Side Effects:
- Limited human data.
- Mild injection site reaction.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Senolytic action — theoretical tissue damage risk
PNC-27 targets HDM2 in cancer cells but in vivo selectivity has not been fully proven. Potential damage to healthy cells. In vitro data only.
📄 Int J Cancer 2006References
- Cancer Biology & Therapy — PNC-27 induces necrosis of cancer cells
View Source - International Journal of Cancer — Mechanism of action of PNC-27
View Source
Recommended Supplements
NMN (Nicotinamide Mononucleotide)
CoQ10 (Ubiquinol)
Vitamin E (Mixed Tocopherols)
External Sources & Regulatory Status
Regulatory Approvals
Research-only — Anticancer peptide (p53 derivative)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →